Compare HOG & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | WVE |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | Singapore |
| Employees | 6400 | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1994 | 2015 |
| Metric | HOG | WVE |
|---|---|---|
| Price | $23.23 | $7.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $24.00 | ★ $29.50 |
| AVG Volume (30 Days) | 3.2M | ★ 6.4M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $4,473,175,000.00 | $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | $85.67 |
| P/E Ratio | $8.22 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $17.09 | $5.02 |
| 52 Week High | $31.25 | $21.73 |
| Indicator | HOG | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 34.60 |
| Support Level | $22.75 | $6.93 |
| Resistance Level | $24.98 | $7.67 |
| Average True Range (ATR) | 0.82 | 0.33 |
| MACD | 0.09 | 0.23 |
| Stochastic Oscillator | 62.44 | 47.80 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.